A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).Michael J. Pishvaian, Jonathan R. Brody, Jimmy J. Hwang et al.|Journal of Clinical Oncology|2013Cited by 24
A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.Michael J. Pishvaian, Jonathan R. Brody, Rebecca Slack et al.|Journal of Clinical Oncology|2011Cited by 6